Vivli has received a grant from the Wellcome Trust, which aims to improve the access and re-use of COVID-related clinical trials data. This will include data from trials funded by the Coronavirus Therapeutics Accelerator (CTA), an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard to speed up the response to the Covid-19 pandemic by identifying, assessing, developing, and scaling up Covid-19 treatments. Vivli has received these funds as part of the consortium’s efforts to encourage and enhance the sharing of COVID-19 data.
“Vivli is delighted that we have received this timely grant from the Wellcome Trust as it will serve to enhance our ongoing efforts in COVID to accelerate access,” said Rebecca Li, Vivli Executive Director. “Coronavirus is currently the most searched term on our Vivli platform.”
Additionally, the grant will help Vivli improve its existing infrastructure to make studies that are available on Vivli easier to find and surface more data usage metrics. In addition, the grant provides funding for Vivli to work with the Infectious Disease Data Observatory (IDDO) to make COVID studies in its platform also available for searching and requesting on Vivli.
The grant will provide funding over a three-year period. Insight Enterprises, Vivli’s long-time partner, will undertake the technical enhancements on the Vivli platform that are linked to this grant.
Vivli is a non-profit organization working to advance human health through the insights and discoveries gained by sharing and analyzing data. It is home to an independent global data-sharing and analytics platform which serves all elements of the international research community. The platform includes a data repository, in-depth search engine and cloud-based analytics, and harmonizes governance, policy and processes to make sharing data easier. Vivli acts as a neutral broker between data contributor and data user and the wider data sharing community. For more information, visit www.vivli.org and follow us on Twitter @VivliCenter.
Launched in 2016, the Infectious Diseases Data Observatory (IDDO) is a scientifically independent, multi-disciplinary coalition of the global infectious disease community. It provides an environment for equitable data sharing as well as the methods and infrastructure to harmonise and translate data into evidence that improves outcomes for patients worldwide. IDDO builds on and incorporates the pioneering work of the WorldWide Antimalarial Resistance Network (WWARN), a collaborative data-sharing framework begun in 2009 that proved it was possible to produce policy-changing scientific evidence from historical data.